Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

TISSUE-SPECIFIC MUTAGENESIS IN RAT AS AN IN VIVO TOOL FOR COLON CANCER GENE DISCO

Award Number: R43CA138336
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/05/2009
PERIOD OF PERFORMANCE END DATE: 04/30/2011

Group Awards By:

View Award Description

TISSUE-SPECIFIC MUTAGENESIS IN RAT AS AN IN VIVO TOOL FOR COLON CANCER GENE DISCO - DESCRIPTION (provided by applicant): The outcome of this SBIR application will be a rat model of colorectal cancer (CRC), which can be used to discover new targets for colon cancer therapy. CRC rats will be produced using Transposagen's novel technology for introducing somatic mutations in rats. A number of germline and somatic mutations are known to contribute to the initiation and progression of both heritable and sporadic CRC, but identifying the causative molecular and genetic defects involved in human CRC has proven difficult. Existing mouse models for CRC do not accurately model human disease. Rats more closely recapitulate the molecular, cellular, and pathologic characteristics of human CRC. Polyps in the rat, unlike in the mouse, progress to adenocarcinomas that are equivalent to stage T1 CRC in humans. Colon cancer induced in normal rats using known human carcinogens will spread to the liver, indicating that the rat, unlike the mouse, may serve as a valuable model for CRC metastasis. The physical size of the rat also makes it much more amenable to endoscopy, thus enabling polyp monitoring and real-time assessment of somatic mutations taking place in a single adenoma, so that gate-keeper mutations can be more accurately discriminated from mutations involved in later stages of carcinogenesis. In Phase I of this application, we will create and characterize three lines of transgenic rats: 1) rats exhibiting intestine-specific expression of a Cre recombinase using a VilCre transgene; 2) rats expressing a transposase (the enzyme responsible for transposon mobilization) gene under the direction of the ubiquitous ROSA26 promoter. A lox-stop-lox cassette will be used to restrict the expression of the transposase; 3) transgenic rats containing a gene trap donor transposon. Cre expression in tri-transgenic rats, created by cross-breeding, will trigger expression of the transposase, which will then mobilize the gene trap transposon and insert it randomly throughout the genome. Importantly, these mutations will occur in the intestine only, because of the tissue-specific expression of the Cre recombinase. Our gene-trap will be capable of creating both null alleles (loss-of-function) and over-expressed transcripts (gain-of-function). A sequence-specific tag is used for mapping mutations, an especially salient advantage compared to other random mutagenesis methods (such as chemical or radiation strategies) for rapid identification of tumor suppressors and oncogenes. In later Phase II work, we will perform a full phenotypic analysis of the CRC phenotype of tri-transgenic rats and clone insertion sites to verify the efficacy of the model. The CRC rat model developed by our method of unbiased transposon mutagenesis in the intestine will likely identify novel cancer genes in a model of colon cancer that is more relevant to human CRC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $141,068 )
2010	2010	TRANSPOSAGEN BIOPHARMACEUTICALS INC	3701 Market St FL 4	Philadelphia	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	001	2	6/21/2010	NON-COMPETING CONTINUATION	$141,068
2010	2009	TRANSPOSAGEN BIOPHARMACEUTICALS INC	3160 CHESTNUT STREET	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	1	11/4/2009	NEW	$0
														Subtotal = $141,068

Issue Date FY: 2009 ( Subtotal = $171,560 )
2009	2009	TRANSPOSAGEN BIOPHARMACEUTICALS INC	3701 Market St FL 4	Philadelphia	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	1	5/1/2009	NEW	$171,560
														Subtotal = $171,560

Grand Total All Awards = $312,628

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TISSUE-SPECIFIC MUTAGENESIS IN RAT AS AN IN VIVO TOOL FOR COLON CANCER GENE DISCO

Award Number: R43CA138336

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/05/2009

PERIOD OF PERFORMANCE END DATE: 04/30/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer